Anemia Management News

Higher preoperative hemoglobin levels are associated with higher mortality in both men and women after CABG, whereas patients with lower limits of normal hemoglobin levels were at greater risk compared with mid‐normal values, data show.

Over time, a declining hemoglobin z score correlates with impaired height among children with mild to moderate nonglomerular chronic kidney disease, according to data published in the American Journal of Kidney Diseases.

The FDA has approved Jesduvroq tablets for treatment of anemia in patients with chronic kidney disease who are on dialysis, according to a press release.

Pediatric patients with anemia and chronic kidney disease can alternate between maintenance erythropoiesis-stimulating agents and subcutaneous continuous erythropoietin receptor activators every 4 weeks, according to a study.

During short exposure and follow-up periods, patients on dialysis with higher hemoglobin concentrations were at a reduced risk for death, hospitalization and ED visits, according to data published in Kidney Medicine.

Weighing the potential benefits for two different kidney patient populations, a review board for the FDA voted 13-3 to approve use of the anemia drug daprodustat for patients with dialysis-dependent chronic kidney disease.

Anemia independently correlated with lower eGFR and an increased risk of end-stage kidney disease, cardiovascular disease, coronary heart disease, stroke, heart failure and death, according to recently published data.

Among patients with African ancestry, those with sickle cell trait are at a higher risk for COVID-19–related death, according to data published in JAMA Internal Medicine.

The National Institute for Health and Care Excellence has recommended Evrenzo (roxadustat) as an option for treating anemia associated with chronic kidney disease in adults with stage 3 to 5 CKD with no iron deficiency.

Following the Medicare reimbursement policy in 2011 that recommended erythropoietin-stimulation agent dosing changes, researchers found reduced dosing and lower hemoglobin levels in anemia care among patients on hemodialysis.